Hormonal Counterregulation and Consecutive Glimepiride Serum Concentrations During Severe Hypoglycaemia Associated with Glimepiride Therapy

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2003 Nov 25

PMID 14634699

Citations 1

Authors

A Holstein

A Plaschke

C Hammer

M Ptak

J Kuhn

C Kratzsch

J Diekmann

K Kleesiek

H H Maurer

E-H Egberts

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the release of counterregulatory hormones and consecutive glimepiride serum concentrations during severe hypoglycaemia (SH) associated with glimepiride therapy.

Methods: In nine type-2 diabetic patients [age 81+/-9 (65-93) years; diabetes duration 9+/-4 (3-15) years; initial blood glucose 33+/-16 (10-54) mg/dl (1.8+/-0.9 mmol/l); HbA1c 7.2+/-1.1 (5.6-8.7)%; creatinine clearance 49+/-33 (15-107) ml/min] who experienced SH associated with glimepiride therapy with neuroglucopenic presentation, insulin, C-peptide, glucagon, epinephrine, norepinephrine, cortisol, adenocorticotrophic hormone (ACTH), human growth hormone (HGH) and pancreatic polypeptide (PP) were determined in blood samples taken at 4-h intervals prior to and during treatment with glucose i.v. Serum from the same samples was screened for sulphonylurea-type oral antidiabetics. Glimepiride concentrations were determined by a validated atmospheric pressure chemical ionization liquid chromatographic-mass spectrometry (APCI-LC-MS) assay.

Results: Once treatment had begun, normoglycaemia was maintained; most glimepiride levels were below the limit of detection (LOD <0.01 mg/l) and further sulphonylureas could be excluded. The secretion of glucagon and epinephrine as counterregulatory hormonal responses was unaffected. In addition, protracted marked increases of cortisol and norepinephrine levels were demonstrated. Protracted stimulation of insulin and C-peptide occurred in a period of up to 24 h after SH. No significant protracted responses were observed for ACTH, HGH or PP.

Conclusion: In SH associated with glimepiride therapy, no correlation between glimepiride serum concentrations and the protracted stimulation of insulin and C-peptide was observed. The secretion of glucagon and epinephrine as counterregulatory hormonal responses was unaffected. Protracted increased release of cortisol might be a medium-term indicator of glimepiride-associated SH.

Citing Articles

Management of diabetes mellitus in patients with chronic kidney disease.

Hahr A, Molitch M Clin Diabetes Endocrinol. 2017; 1:2.

PMID: 28702221 PMC: 5469199. DOI: 10.1186/s40842-015-0001-9.

References

DORSCHNER H, Brekardin E, Uhde I, Schwanstecher C, Schwanstecher M . Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol Pharmacol. 1999; 55(6):1060-6. DOI: 10.1124/mol.55.6.1060. View

KREPINSKY J, Ingram A, Clase C . Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000; 35(3):500-5. DOI: 10.1016/s0272-6386(00)70204-6. View

Melander A, Donnelly R, Rydberg T . Is there a concentration-effect relationship for sulphonylureas?. Clin Pharmacokinet. 1998; 34(3):181-8. DOI: 10.2165/00003088-199834030-00001. View

Holstein A, Plaschke A, Egberts E . Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2002; 17(6):467-73. DOI: 10.1002/dmrr.235. View

Spyer G, Hattersley A, MacDonald I, Amiel S, MacLeod K . Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet. 2000; 356(9246):1970-4. DOI: 10.1016/s0140-6736(00)03322-5. View

Kwong P, Teale J . Screening for sulphonylureas in the investigation of hypoglycaemia. J R Soc Med. 2002; 95(8):381-5. PMC: 1279961. DOI: 10.1258/jrsm.95.8.381. View

Balant L, ZAHND G, Weber F, Fabre J . Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol. 1977; 11(1):19-25. DOI: 10.1007/BF00561783. View

Sills M, Ogu C, Maxa J . Prolonged hypoglycemic crisis associated with glyburide. Pharmacotherapy. 1997; 17(6):1338-40. View

Badian M, Korn A, Lehr K, Malerczyk V, Waldhausl W . Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact. 1996; 13(1):69-85. DOI: 10.1515/dmdi.1996.13.1.69. View

10.

Asplund K, Wiholm B, Lithner F . Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 1983; 24(6):412-7. DOI: 10.1007/BF00257338. View

11.

Holstein A, Plaschke A, Hammer C, Egberts E . Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol. 2003; 59(2):91-7. DOI: 10.1007/s00228-003-0592-4. View

12.

Sugarman J . Hypoglycemia associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1991; 14(2):139-47. DOI: 10.1016/0168-8227(91)90120-3. View

13.

Heller S, MacDonald I, Tattersall R . Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis. Diabetologia. 1987; 30(12):924-9. DOI: 10.1007/BF00295875. View

14.

Rydberg T, Melander A . Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatogr. 1991; 564(1):223-33. DOI: 10.1016/0378-4347(91)80084-p. View

15.

Strachan M, Abraha H, Sherwood R, Lammie G, Deary I, EWING F . Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes Metab Res Rev. 1999; 15(1):5-12. DOI: 10.1002/(sici)1520-7560(199901/02)15:1<5::aid-dmrr2>3.0.co;2-s. View

16.

Segel S, Paramore D, Cryer P . Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002; 51(3):724-33. DOI: 10.2337/diabetes.51.3.724. View

17.

Peacey S, George E, Rostami-Hodjegan A, Bedford C, Harris N, Hardisty C . Similar physiological and symptomatic responses to sulphonylurea and insulin induced hypoglycaemia in normal subjects. Diabet Med. 1996; 13(7):634-41. DOI: 10.1002/(SICI)1096-9136(199607)13:7<634::AID-DIA136>3.0.CO;2-Z. View

18.

Landstedt-Hallin L, Adamson U, Lins P . Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999; 84(9):3140-5. DOI: 10.1210/jcem.84.9.6002. View

19.

Hellman B, Sehlin J, Taljedal I . Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets. Acta Endocrinol (Copenh). 1984; 105(3):385-90. DOI: 10.1530/acta.0.1050385. View

20.

Harrigan R, Nathan M, Beattie P . Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med. 2001; 38(1):68-78. DOI: 10.1067/mem.2001.114314. View